



Latest Advances in Human Papillomavirus (HPV) Research

Guest Editors:

Dr. Paul Licciardi

Infection and Immunity, Murdoch
Children's Research Institute,
Parkville, VIC 3052, Australia

Dr. Zheng Quan Toh

Infection and Immunity, Murdoch
Children's Research Institute,
Parkville, VIC 3052, Australia

Deadline for manuscript
submissions:

closed (31 December 2023)

Message from the Guest Editors

Dear Colleagues,

Human papillomavirus (HPV) causes a range of diseases from benign anogenital warts to anogenital cancers, particularly cervical cancer. HPV was first discovered to cause cervical cancer in the 1980s, and since then, there have been several major scientific breakthroughs that have led to the development and implementation of highly effective prophylactic HPV vaccines, cervical cancer screening programs, and treatment of cervical lesions. These important discoveries build upon key basic science research and technological advancement that has enabled novel discoveries within HPV research. In 2018, the Director-General of the World Health Organization made a pledge to eliminate cervical cancer as a public health problem within the next century and outlined a strategy encompassing HPV vaccination, screening, and treatment. This Special Issue aims to present the latest research into HPV in the hope that it will contribute new knowledge to the field as well as ultimately aid in achieving the cervical cancer elimination goal.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Lawrence S. Young

Warwick Medical School,
University of Warwick, Coventry
CV4 7AL, UK

Message from the Editor-in-Chief

The worldwide impact of infectious disease is incalculable. The consequences for human health in terms of morbidity and mortality are obvious and vast but, when infections of animals and plants are also taken into account, it is hard to imagine any other disease that has such a significant impact on our lives—on healthcare systems, on agriculture and on world economics. *Pathogens* is proud to continue to serve the international community by publishing high quality studies that further our understanding of infection and have meaningful consequences for disease intervention.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, PubAg, CaPlus / SciFinder, AGRIS, and other databases.

Journal Rank: JCR - Q2 (*Microbiology*) / CiteScore - Q2 (*General Immunology and Microbiology*)

Contact Us

Pathogens Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pathogens
pathogens@mdpi.com
[X@Pathogens_MDPI](https://twitter.com/Pathogens_MDPI)